Molecules and methods for modulating TMEM16A activities

US9045546B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Larry Alexander Gaither · Cambridge, US
• Christopher John Rothwell · Swampscott, US

Key dates

• Filing date: Nov 30, 2012
• Grant date: Jun 2, 2015
• Expiry date: Nov 30, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides molecules that bind to TMEM16A (“TMEM16A binding molecules”), particularly human or humanized antibodies and antibody drug conjugates that bind to human TMEM16A and modulate its functions. Epitopes of TMEM16A and molecules that bind these epitopes are also provided herein.